rs6833641 — ARAP2

Intergenic variant near ARAP2 associated with motion sickness susceptibility at genome-wide significance; one of only three loci from the first motion sickness GWAS to also associate with postoperative nausea and vomiting, making it clinically relevant for pre-surgical risk assessment

See your personal result for ARAP2

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

ARAP2 rs6833641 — Motion Sickness, PONV, and a Pre-Surgical Genetic Signal

Motion sickness is not simply a matter of willpower. The nausea, cold sweats, and vomiting triggered by travel in cars, boats, or aircraft have a substantial heritable component — twin studies estimate heritability at around 57–70%. The first genome-wide association study of motion sickness, published by Hromatka et al. in 2015 using 80,494 participants from the 23andMe database11 80,494 participants from the 23andMe database
Hromatka BS et al. Genetic variants associated with motion sickness point to roles for inner ear development, neurological processes and glucose homeostasis. Human Molecular Genetics, 2015, identified 35 loci at genome-wide significance. Among them, rs6833641 — a variant near the ARAP2 gene22 ARAP2 gene
ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 2; a multidomain GTPase-activating protein that regulates Arf6-mediated integrin trafficking, focal adhesion dynamics, and endosomal sorting, with notable expression in brain and inner ear tissues on chromosome 4p15.1 — achieved p=1.8×10⁻⁹ with a beta of +0.046 per G allele on a four-point severity scale.

What makes rs6833641 clinically distinctive is its dual association. Of the 35 motion sickness loci, only three also reached statistical significance for postoperative nausea and vomiting33 postoperative nausea and vomiting
PONV is one of the most common surgical complications, affecting 20–30% of general surgical patients and up to 80% of high-risk groups; ondansetron prophylaxis is standard of care for high-risk patients (PONV). rs6833641 was one of them, with P=0.00101 and effect=0.09 for PONV in an independent surgical cohort. Motion sickness and PONV share overlapping neural circuitry involving the chemoreceptor trigger zone and the nucleus tractus solitarius — but a genetic variant that predicts both simultaneously is far more actionable than one predicting only the recreational nuisance.

The Mechanism

rs6833641 sits in an intergenic region approximately 66 kb upstream of the nearest gene annotation at this locus, in a region tagged as near ARAP2 in the GWAS. ARAP2 encodes a large multidomain protein containing ArfGAP, RhoGAP, ankyrin repeat, and five pleckstrin homology (PH) domains. Its primary catalytic activity is as an Arf6 GTPase-activating protein44 Arf6 GTPase-activating protein
GTPases are molecular switches; GAPs (GTPase-activating proteins) accelerate GTP hydrolysis, switching the GTPase off. Arf6 controls membrane trafficking at the cell surface and endosomes, including recycling of integrins to focal adhesions. ARAP2 functions downstream of RhoA to regulate focal adhesion morphology, α5β1 integrin endosomal compartmentalisation, and actin cytoskeleton organisation. The gene is expressed in brain tissue (RPKM 5.8) and broadly across 22 additional tissues including the inner ear region.

The precise mechanism by which regulatory variation near ARAP2 modulates vestibular nausea circuits is not yet characterised. The Hromatka 2015 study points toward roles in inner ear development and neurological signal processing — both of which depend on the kind of membrane trafficking and cytoskeletal organisation that ARAP2 coordinates. rs6833641 likely acts as a regulatory variant that alters ARAP2 expression in relevant vestibular or brainstem neurons, but direct functional studies are lacking.

The Evidence

The primary evidence comes from Hromatka et al. 201555 Hromatka et al. 2015
Genetic variants associated with motion sickness point to roles for inner ear development, neurological processes and glucose homeostasis. Human Molecular Genetics, the first and largest motion sickness GWAS, with 80,494 participants. The study used a validated four-point motion sickness severity scale and identified rs6833641 as a genome-wide significant hit (p=1.8×10⁻⁹). Each additional G allele was associated with a beta of +0.046 on the severity scale — a modest per-allele effect consistent with the polygenic architecture of motion sickness.

Critically, the study also tested all 35 motion sickness SNPs for association with PONV in an independent dataset. Of the 35 loci, only rs6833641, rs1195218 (near AUTS2), and rs6069325 (near CBLN4) reached significance for PONV as well. For rs6833641, the PONV association had p=0.00101 and effect=0.09. This cross-phenotype replication is important: it suggests that the neural pathways modulated by ARAP2-region variation contribute to emesis circuitry broadly, not just to vestibular-triggered symptoms.

The G allele — the risk allele — is the common allele, present in approximately 85% of the study population. This makes the C allele a protective minor variant, carried in usefully detectable frequency only in European populations (~7–15% C allele frequency; near-absent in East Asian, African, South Asian, and Latin American populations based on ALFA and 1000 Genomes data).

Practical Actions

For GG individuals (approximately 73% of the population): pre-surgical disclosure of motion sickness history to the anaesthesiology team is the most actionable implication. The genetic link between motion sickness susceptibility and PONV supports early prophylactic antiemetic administration — standard first-line agents include ondansetron (a 5-HT3 antagonist), dexamethasone, and scopolamine. In transit, GG carriers benefit from front-of-vehicle seating, horizon fixation, and prophylactic scopolamine patches or antihistamine premedication for predictable motion exposures.

For GC heterozygotes: partial G-allele dosage means intermediate susceptibility. The same pre-surgical disclosure applies, though PONV risk is statistically lower than in GG.

For CC individuals: the C allele is associated with reduced motion sickness susceptibility and the statistical PONV signal is attenuated.

Interactions

The dual motion sickness/PONV association at rs6833641 places it in the company of rs1195218 (near AUTS2, involved in neuronal development) and rs6069325 (near CBLN4, a cerebellin involved in synapse formation). These three loci likely converge on shared brainstem emesis circuitry — the chemoreceptor trigger zone and the area postrema. Whether carrying risk alleles at multiple loci compounds PONV risk additively has not been directly tested; the GWAS paper did not report interaction analyses for the three dual-association SNPs.

Genotype Interpretations

What each possible genotype means for this variant.

CC Motion-Protective Genotype Beneficial

Rare protective genotype — reduced motion sickness and PONV susceptibility

You carry two copies of the C allele at rs6833641, the rare protective genotype. Approximately 2% of people of European descent share this genotype; it is near-absent in East Asian, African, South Asian, and Latino populations. In the first motion sickness GWAS of 80,494 individuals, the C allele was associated with reduced motion sickness susceptibility. Your CC genotype means you carry zero copies of the G risk allele, placing you at the lowest genetic susceptibility to both motion sickness and postoperative nausea and vomiting (PONV) among the three possible genotypes at this locus.

CG Intermediate Susceptibility Intermediate

One G risk allele — moderate genetic susceptibility to motion sickness and PONV

rs6833641 was one of only three loci in the study to associate with both motion sickness (p=1.8×10⁻⁹) and PONV in an independent surgical cohort (p=0.00101, effect=0.09). The variant sits near the ARAP2 gene, which encodes an Arf6 GTPase-activating protein involved in inner ear-related trafficking and neuronal signalling. As a GC heterozygote, you carry one G allele whose modest additive effect raises your vestibular nausea threshold above that of CC individuals but below GG homozygotes.

GG High Motion Susceptibility High Risk

Two G risk alleles — highest genetic susceptibility to motion sickness and PONV

The Hromatka 2015 study identified rs6833641 (p=1.8×10⁻⁹, beta=+0.046 per G allele) as a genome-wide hit near ARAP2, a gene encoding a multidomain Arf6 GTPase-activating protein expressed in brain and inner ear tissue. PONV and motion sickness share overlapping neural circuitry at the chemoreceptor trigger zone and area postrema. Of 35 motion sickness loci, only three — including rs6833641 — also reached statistical significance for PONV (p=0.00101, effect=0.09 per G allele) in an independent surgical dataset.

The G allele is common (~85% frequency), so GG is the most common genotype. The per-allele effect is modest (beta=0.046 on a 4-point scale), but two G alleles represent the maximum dosage at this locus. Motion sickness susceptibility is polygenic, so this variant is one signal among many — but its direct relevance to PONV makes the pre-surgical disclosure recommendation unusually concrete and actionable.

The C protective allele is predominantly found in European populations (~7–15% C allele frequency) and is near-absent in East Asian, African, South Asian, and Latino populations, meaning that most people globally are in the GG or GC genotype category.